

# Cutting Eugenics Out of CRISPR-Cas9

Carolyn Brokowski,<sup>a,\*</sup> Marya Pollack,<sup>b</sup> & Robert Pollack<sup>c</sup>

<sup>a</sup>Bioethics (Medical Ethics) Department, Columbia University School of Professional Studies, New York, New York; <sup>b</sup>Department of Psychiatry, Columbia University College of Physicians and Surgeons, Inwood Clinic, New York, New York; <sup>c</sup>Biological Sciences Department, Columbia University School of the Arts, New York, New York

\*Address all correspondence to: Carolyn Brokowski, M.S. Candidate; Bioethics (Medical Ethics) Department, Columbia University School of Professional Studies, 203 Lewisohn Hall, 2970 Broadway, MC 4119, New York, NY 10027; E-mail: ceb2185@columbia.edu

**ABSTRACT:** The use of clustered regularly interspaced short palindromic repeats (CRISPR) and their associated (Cas) proteins (the CRISPR-Cas system) in genomic engineering is among the most promising biomedical innovations to occur in the last few decades. One of this system's most profound features is its ability to edit genomes with impressive specificity, which may cause significant alterations of cellular, tissue, and organismal phenotypes at the near instance of the editing, over the lifespan of the organism and potentially into any number of future generations. We argue that the use of the CRISPR-Cas9 system to edit the human germline should be legally prohibited on account of the system's potential for generating an unjust eugenic future. Its use in nongermline experimentation and applications, however, should not be constrained on eugenic grounds. Such a blanket legal prohibition might limit the progress gleaned from this technology. Allowing experimentation in human subjects more broadly might expose participants to considerable risk and potentially harmful outcomes, and the system might prove unable to realize tangible therapeutic outcomes that seem likely *ex ante*. We conclude that the uncertainty inherent in CRISPR use should not lead to reflexive, preemptive prohibitions, but instead to ethical, fastidious, and controlled experimentation.

**KEY WORDS:** bioengineering, bioethics, gene editing, genomic engineering, germline editing, medical ethics, research ethics, research involving human subjects

## I. INTRODUCTION

*Within the infant rind of this weak flower, Poison hath residence, and medicine power; - Friar Laurence, Romeo and Juliet*<sup>1</sup>

The clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas)9 system has expanded the terrain of biomedical innovation.<sup>2,3</sup> Because of its genome altering capabilities, it has been employed for at least the following uses: constructing novel genomic libraries and genetic screens;<sup>4–11</sup> creating genetically modified (both knock-out and knock-in) organisms,<sup>12–16</sup> ranging from viruses to silkworms to primate embryos;<sup>17–22</sup> analyzing epigenetic modifications and genomic regulation;<sup>23–25</sup> growing genetically modified plants and foods such as rice and wheat;<sup>26–28</sup> modulating transcription and metabolism;<sup>29–31</sup> modifying the mitochondrial genome;<sup>32</sup> and analyzing and editing gene function in the genome *in vivo*.<sup>33,34</sup> In addition, CRISPR systems

currently are being engineered not only to edit the genome permanently, but also to target regulation without permanent genomic sequence alterations through the use of a “dead” version of a Cas9 enzyme that may act as a platform for activator and repressor molecules. In this instance, the guide RNA brings the Cas-9 molecule to a specific gene regulatory site on the DNA, but the modified protein cannot initiate a DNA modification. Instead, it may act as a platform for activator and repressor molecules.<sup>35</sup> CRISPR-Cas9 is also thought to hold great promise for studying and potentially offering therapeutic modalities for cancer,<sup>36–39</sup> muscular dystrophy,<sup>40,41</sup> parasitic and bacterial infections,<sup>42–44</sup> neurodegenerative conditions,<sup>45</sup> human immunodeficiency virus,<sup>46</sup> and other diseases.

Its promise derives largely from its ability to interact with genomic material with great specificity. Such specificity enables key gene and regulatory regions to be altered, presumably with few, if any, off-target effects and unintended biological consequences. Some off-target effects have been observed, though their frequency and causal weight in determining the phenotypic outcomes of the genetic modifications remain uncertain at this time. Therefore, at the time of this writing it seems reasonable that genetic and genomic modifications of many varieties may produce intended changes in phenotypes in cells, tissues, and whole organisms in a fairly controlled manner. Although it is impossible to determine in advance which modifications will ultimately produce desired, specified phenotypic alterations, most likely there will be at least *some* instances when CRISPR genomic modifications will yield precise, intended phenotypic changes. We argue that while the use of CRISPR-Cas9 in manipulating the human germline should be legally banned because of concerns about rational and irrational eugenics, its nongermline experimentation and applications in humans (i.e., infants, children, adolescents, and adults) may be permissible on account of the system’s promise.

Firstly, we briefly review the CRISPR-Cas9 system, addressing the specificity and the possible side effects of its ability to alter regulation of sequences and genomes regulation. We then appraise many possible benefits of CRISPR-Cas9 and show why its application may be helpful in advancing our understanding of basic science, biotechnology, and medicine. Secondly, we argue that germline modification by this system facilitates the return of eugenics—the positive selection of the “good” or “desirable” versions of the human genome and a marginalization that becomes a form of negative selection of those that are unmodified and therefore “bad” or “undesirable.”<sup>47</sup> A brief reflection on both international and national historical events reveals that, however they have been rationalized, legalized eugenics laws and policies have not produced just or even reasonable societal outcomes for many.

Finally, we address three limitations of our argument. First, allowing the CRISPR-Cas9 application for only nongermline editing purposes may limit many of its potential uses in advancing biomedicine. We hold that this restriction is justified, nevertheless, given the risks of improper usage. Second, permitting experimentation, even in nongermline contexts, may pose significant risks to human subjects, due to the possibility of sizeable off-target effects that may broadly and inappropriately alter physiological and developmental trajectories. But we hold that with appropriate ethical and legal oversight as mandated by the Common Rule<sup>48</sup>—the United States federal regulations that apply to 17 federal


agencies overseeing the ethical conduct of human subjects research—such risks may be justified depending on the specifics of the medical research contexts. Third, because of our inability to predict the relative weight of genomic alteration versus individual experience and its epigenetic effects on organisms' phenotypic properties (whether at the level of cells, tissues, or entire organisms) in both the short and long term, there may be a limited probability of actualizing therapeutic outcomes through genomic modulation. Implementing CRISPR genomic modification, when the probability of therapeutic effects is small, indeed opens a possibility that the risks of its use in human subjects might outweigh the benefits of experimentation on them. We maintain, however, that whether such modifications result in positive therapeutic outcomes is an empirical question free from the novel burdens of inadvertent or intentional eugenic consequence.

### **A. The CRISPR-Cas9 System and Its Prodigious Potential for Advancement**


CRISPR-Cas systems are found abundantly in bacteria and archaea,<sup>49</sup> providing them with acquired immunologic defenses against invading plasmids and viruses.<sup>50,51</sup> Structural features of CRISPR loci enable these systems to combat a variety of threats (Figure 1).<sup>52,53</sup> For example, these loci typically contain *cas* genes (CRISPR-associated genes), a leader sequence, and a repeat-spacer array.<sup>54</sup> The family of *cas* genes encodes proteins such as helicases and nucleases,<sup>55</sup> which are enzymes that unwind and cut DNA, respectively. The leader sequence, which is directly adjacent to the short repeats (tens of base pairs),<sup>56</sup> is in a fixed orientation flanking one side of the CRISPR loci. This leader sequence is several hundred base pairs long, and is well conserved.<sup>57</sup> In bacteria, the repeat-spacer array consists of repeat sequences of bacterial DNA in addition to spacers interspersed between the repeats. It is thought that the spacers are derived from invader (e.g., phage and plasmid) DNA. In the invading DNA, spacers are referred to as proto-spacer adjacent motifs (PAMs).

Although three main CRISPR types have been characterized,<sup>58</sup> we will focus upon type II in bacteria. In all cases, when invaders attack during the adaptive phase, bacteria respond by integrating the invader's protospacers into the host's CRISPR locus. Next, CRISPR RNAs (crRNAs) are transcribed from this locus and then incorporated into effector complexes, where the crRNA guides the complex to the invading nucleic acid; Cas proteins then degrade it. In the type II system, a transactivating-crRNA (tracrRNA) binds complementarily to the repeat sequences of pre-crRNA resulting in duplex formation. This is cleaved by the RNA ribonuclease (RNase III), forming a crRNA:tracrRNA complex, which then facilitates Cas9 in degrading the invading nucleic acid by creating double-strand breaks in it.

The type II CRISPR-Cas9 system may be designed to enable "RNA-programmable" site-specific genomic modifications.<sup>59</sup> A guide RNA, formed from a hybrid of crRNA:tracrRNAs, recruits Cas9, and then binds to a target DNA sequence through complementary base pairing. Upon the binding of the guide RNA to the double-stranded regions of choice, Cas9 then may create double-strand breaks (Figure 2).<sup>53,60</sup> Normally, after DNA experiences double-strand



**FIG. 1:** The type II CRISPR-Cas9 system from *Streptococcus pyogenes* (bacteria) is well characterized. Major defining structural features include the following: *cas* genes encoding the Cas9 endonuclease; a leader sequence; genome-targeting spacers in between the repeats, which may contain palindromic sequences; and DNA coding for transactivating RNA (tracrRNA).



**FIG. 2:** After several important processing events, transactivating-RNA (tracrRNA) is paired to CRISPR RNA (crRNA) and bound to the Cas9 endonuclease. The tracrRNA:crRNA hybrid acts as a guide RNA, directing Cas9 to the desired cognate target DNA. Once inside the nucleus of a cell, the complex locks onto the protospacer adjacent motif (PAM) sequence (5' NGG 3' for *Streptococcus pyogenes*). Cas9 endonuclease unzips the DNA and matches it to its target RNA. Upon matching, Cas9 cuts the DNA, creating double-strand breaks. To fix the breaks, mammalian cells may employ one of two principal DNA repair mechanisms. Homology-directed repair (HDR) (lower left) can generate precise, defined modifications at target loci by employing an exogenously introduced repair template. Precise genome edits, including the introduction of several or single nucleotide mutations (solid green line), are possible. HDR occurs only in dividing cells, and there is considerable variability in its efficiency. Alternatively, in nonhomologous end joining (NHEJ) (lower right), a repair template is absent; double-strand breaks are simply religated. This process is error prone and can result in insertions and deletions, which might create a premature stop codon terminating translation.

breaks, enzymes detect and repair them, typically by ligating both ends or by homology repair, where donor DNA that has sequences matching the site of the breaks can be integrated into the genome. In the latter way, genetic information may be significantly and precisely altered by addition, deletion, or other sequence modification.

Theoretically, CRISPR-Cas9 should permit reversing the modifications. However, whether it is possible under any conditions for a given phenotype to revert to its premodification state remains to be determined. In addition, the system may be used to edit the genome epigenomically, by chemically modifying, but not altering, its base pair sequences themselves. One approach involves inactivating the Cas9 enzyme such that, instead of cutting DNA, it is used only for regulating gene expression. Nevertheless, both nucleic acid sequence modifications and directed epigenetic changes in regulatory control brought on by the use of “dead” versions of Cas-9 affect gene expression in critical ways: both affect the phenotypic outcome to which they are causally tied, albeit perhaps to different extents. As such, it seems that there is no material basis for the claim that either approach would entirely avert ethical concerns about the use of the CRISPR-Cas9 system in humans.

Completely banning the use of CRISPR-Cas systems would be to deprive the world of considerably promising innovation that may have far-reaching beneficial effects for humanity (Table 1).<sup>5,7,9,10,15,23,28,32,33,39,42,43,61–84</sup> Yet great power should command great responsibility. Accordingly, it is critical to manage risk.

## **B. A Legal Prohibition Against Germline Experimentation is Warranted to Avert Eugenics**

CRISPR system use in nongermline experimentation and applications in nongermline tissues of embryos, infants, children, adolescents, and adults should be legally permissible because of the system’s probable ubiquitous capacity for biomedical advancement (Table 1). Because of the important relationship of genomic modification at critical growth and developmental periods, it is essential to allow for interventions across an organism’s lifespan. For example, during the third week of human gestation, neural tube closure commences in the developing embryo, and the success of this process requires many timed signaling genetic events to be executed properly.<sup>85</sup> Contributions from WNT, SHH, retinoic acid, and genes affecting the cell cycle; apoptosis; the integrity of the extracellular matrix and cell surface; and regulatory machinery controlling these events all play critical roles in determining neural tube closure.<sup>86,87</sup> Altering abnormal gene sequences themselves, or their expression levels (or both), may result in beneficial short- and long-term effects and help to prevent and ameliorate conditions such as anencephaly, iniencephaly, encephalocele, and spinal bifida.<sup>88</sup>

But, if creating gene modifications should be legal and encouraged at the aforementioned stages, why impose a ban at the germline level? One plausible reason is that germline modification has a direct connection with eugenics. History reveals that societies where it has been legalized often have had great difficulty managing it without severe human rights concerns and violations.

TABLE 1: CRISPR-Cas9 Innovations

Discipline	Author(s)	Contribution
Basic science	Basset et al. (2013)	Highly efficient mutagenesis in <i>Drosophila</i>
	Basset et al. (2015)	Genome-wide CRISPR library for high-throughput screening
	Bhattacharya et al. (2015)	Loss of function tool to screen human disease genes in <i>Xenopus</i>
	Carroll et al. (2015)	Mouse model for cardiac-specific gene deletion
	Flowers et al. (2014)	Highly efficient mutagenesis screen in axolotl
	Hilton et al. (2015)	Epigenome editing
	Hodgkins et al. (2015)	Database for genome engineering
	Li et al. (2015)	Metabolic engineering of <i>Escherichia coli</i>
	Nihongaki et al. (2015)	Optogenetic genome editing
	Ran et al. (2015)	<i>In vivo</i> genome editing
	Wang et al. (2014)	Genetic screens in human cells
	Yang et al. (2014)	Generation of genetically modified mice
	Biomedicine	Bellec et al. (2015)
Bogerd et al. (2015)		Transcription activators may be used in screening for endogenous genes that affect virus replication
Chen et al. (2015)		Engineering human stem cell lines with inducible knock out
Fujii et al. (2015)		Genetic engineering of human intestinal organoids
Hammond et al. (2015)		Gene drive system in malaria
Hart et al. (2015)		Cancer genetics
Jing et al. (2015)		RNA (miR-155) genome knockout in human macrophage cell lines
Jo et al. (2015)		Mitochondrial genome editing

TABLE 1: (continued)

Discipline	Author(s)	Contribution
<b>Biomedicine</b> (Continued)	Hou et al. (2015)	Human CXCR4 gene is efficiently disrupted by genome editing, leading to HIV-1 resistance of human primary CD4+ T cells
	Long et al. (2014)	Prevention of muscular dystrophy in mice
	Shi et al. (2015)	Identification of potential cancer drug targets
	Sollelis et al. (2015)	Genome editing in parasites
	Vinayak et al. (2015)	Genetic modification of diarrheal pathogen
	Yang et al. (2015)	Inactivation of endogenous porcine retroviruses
<b>Biotechnology</b>	Čermák et al. (2015)	Modification of the tomato
	Du et al. (2016)	Mutagenesis in soybeans
	Jiang et al. (2014)	Evidence that the system is applicable in algae
	Ito et al. (2015)	Possible application to tomato fruit ripening
	Li et al. (2014)	Describing methods for genome editing in Arabidopsis and tobacco
	Li et al. (2015)	Soy bean genome editing
	Mikami et al. (2015)	Optimized mutagenesis in rice
	Shan et al. (2014)	Protocol for genome editing in rice and wheat
	Svitashev et al. (2015)	Targeted editing in maize
	Woo et al. (2015)	DNA-free genome editing in plants

An obvious example of such misuse occurred in Nazi Germany. German social Darwinists, many of whom were well-respected physicians and scientists, feared the overall degeneration of the human race and therefore promoted racial hygiene policies (*Rassenhygiene*), whose goal was to provide preventive medicine for the “German germ plasm” by legally blocking the “breeding of inferiors,” by mocking the choices of celibacy and birth control, and by marginalizing feminists who threatened the reproductive performance of the family unit.<sup>89,90</sup> Social Darwinism, with its rhetorical misuse of natural selection to order diverse social phenomena in terms of survival of a “race” within the human species, and eugenics-promoting policies with the support of state authority,



triggered massive widespread abominations. These included the sterilization of hundreds of thousands of individuals and the deliberate, selective ethnic cleansing of millions via euthanasia programs, death camps, and other egregious crimes against humanity.<sup>91</sup>

France, Brazil, Denmark, Britain, Russia, and the United States also enacted eugenic laws.<sup>92–94</sup> Even though the legalization of eugenics did not result in equivalent atrocities on the same scale, severe legal injustices pervaded in many cases. In the early twentieth century in the United States, for example, eugenicists were greatly concerned with the sexual behavior of the “feebleminded”—persons who may or may not have had psychiatric illnesses or neurological limitations of some variety. To prevent these individuals from reproducing successfully, Indiana in 1907 was the first state to pass mandatory sterilization laws; over time, more than 30 additional states followed suit.<sup>95,96</sup> Involuntary sterilization policies created great marginalization and injustices for anyone perceived as mentally inferior, regardless of the truth of the diagnosis. Consider, for instance, the 1927 Supreme Court case *Buck v. Bell*.<sup>97</sup> Carrie Buck was considered a feebleminded woman and as a result was institutionalized in a state psychiatric facility. Her condition purportedly had been in her family for three generations, and she was to be the first person subjected to mandatory sterilization under Virginia law. Hence, the validity of the Virginia statute permitting sterilization of the mentally ill for eugenic purposes was in question before the Court.<sup>98</sup> More specifically, the question at hand was whether the law denied Bell the right to substantive due process and equal protections under the 14th Amendment. Associate Justice Oliver Wendell Holmes famously upheld the law, infamously arguing, “The principle that sustains compulsory vaccination is broad enough to cover cutting the Fallopian tubes. Three generations of imbeciles are enough.”<sup>98</sup> Ironically, the evidence of the case strongly suggests that there were no imbeciles in any of the generations involved.<sup>99</sup> But in any case it is not obvious today why state interest should have led to sterilization, except for the presence of a eugenic component to United States law at that time emerging from the eugenic notion of serving public health through the selective weeding and breeding of people.

But how, if at all, might eugenics via the use of the CRISPR-Cas9 system for germline modifications result in oppressive, harmful future outcomes? It might not. This bioengineering technology might be the biomedical invention par excellence. However, if possible, and for the right price, some will seek to employ the system for nonmedical purposes, such as eye and skin color modifications, boosting intelligence and height, and altering other traits. Although this is an empirical matter, with growing economic disparities on the rise in America,<sup>100</sup> it is plausible that this technology will only exacerbate our unfortunate situation. Those in higher income brackets will have access to methods of creating “designer” children, leaving to the fates the genetics of those with more modest means.<sup>101</sup> This risks the creation of a de facto tiered biological class system, perhaps resulting in even greater inequalities than those existing based on race.

What if the use of the CRISPR-Cas system in germline modifications were only legalized for strictly therapeutic purposes? At the time of this writing, whether CRISPR can be employed successfully for *any* therapeutic purposes is undetermined and in need



of rigorous experimentation through carefully controlled clinical trials involving human subjects. Admittedly, we cannot advance to this testing stage with a legal prohibition in place.

Why, then, is the germline ban necessary? A practical reason in favor of the ban is that the probability of off-target genotypic, and therefore phenotypic, effects remains uncertain; reports about CRISPR-Cas9 efficiency are conflicting.<sup>102–111</sup> Before the introduction of drugs and other pharmaceutical products into humans, United States federal law requires that significant data about the toxicity and physiological effects of the agents must be obtained first by testing in animals.<sup>112</sup> Because of the uncertainty associated with off-target effects, a similar protocol for CRISPR-Cas9 should be followed in humans. Until the technology of targeting with absolute specificity is developed, and until the consequences of off-target DNA modification are better understood, the risk to human subjects exposed to germline modification would be too great to justify potential benefits. Moreover, when more reliable animal data arise, to better understand efficiency limitations of the system, it will be optimal to begin testing with nongermline modification and then possibly reevaluating whether germline modification for therapeutic purposes seems like a reasonable experimental or therapeutic option.

CRISPR-Cas9 genomic engineering does not exist in a vacuum. Clearly, the ways in which it influences societal outcomes are an empirical matter, and even the best intentions about how it *should* be used are insufficient to determine how it *will* be used. Other factors, such as economic conditions and the medico-legal structures and norms of the society, contribute just as much if not more in shaping such outcomes. Moreover, to avert potentially grave harms to human subjects, it is optimal to determine the system's efficiency in nongermline contexts before considering experimentation with the germline, even for therapeutic purposes; such data will contribute to informed decision making, instead of merely firing shots in the dark. Finally, under the best of possible outcomes with respect to safety, efficacy, and specificity, a person born of one or two gametes with modified germlines will be inherently different, from infancy on. The risk is that such a person will be, in social and political terms, also inherently better. Completely successful, completely benign germline modification through CRISPR would in this way lead to a social upheaval that would end the possibility of equal justice and equal citizenship.

### **C. Limitations on Innovative Potential, Safety, and the Ability to Actualize Therapeutic Outcomes**

At least three potential objections to our position may arise. One is that the legal prohibition on CRISPR-Cas9 germline editing may limit the knowledge, experimentation, and overall progress gleaned from this technology. For instance, though it affects the pancreas, intestines, kidneys, and liver, cystic fibrosis (CF) primarily is a lung disorder characterized by the accumulation of unusually thick, sticky mucus that is the site of frequent infections. Most cases of CF are caused by an autosomal recessive mutation in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene, resulting in a misfolded CFTR protein channel.<sup>113</sup> The CFTR channel regulates the flow of water and

chloride ions through cells. CFTR mutations lead to blockage of the channel and consequently, to the development and buildup of abnormal mucus and to chronic infections. If CRISPR-Cas9 editing was approved for germline modification, CF carriers could have their genomes edited to restore the mutated *CFTR* gene to a fully functional, unaffected copy. In this way, these individuals would be able to avoid passing on a mutated copy to their immediate offspring and to subsequent generations.

Although this seems like a promising idea, even if CRISPR-Cas genome editing was guaranteed to produce a wildtype *CFTR* gene—through substitution, sequence modification, or regulatory alterations—concerns about off-target effects remain. For the reasons discussed in the previous section, it seems optimal to first experiment in nongermline contexts. Such experimentation could take place, for instance, *in vivo* during lung development. However, the details about the risk involved would depend upon the specifics of the proposed research.

A second potential problem with our argument is that even nongermline experimentation may expose human subjects to considerable risk and potentially devastating biological outcomes, such as severe injury, disability, or death. And with genomic engineering, there is the risk that modifications may be imprinted permanently. If a gene were modified using the CRISPR-Cas system, then the same system should in principle be available to reverse the modification at a later time. But with the passage of time, it would not be possible to be certain that a sequence reversal would generate a complete phenotypic reversal in cells and tissues descended from the originally modified cells or gametes. If a gene was modified using the CRISPR-Cas system, then it is likely that there would be a mechanism to reverse the modification. But as mentioned earlier, it is difficult to know whether phenotypic effects of the alteration can be reversed to their premodification state. It likely would depend on the phenotypes (proteins, cells, tissues, organisms) in question and the extent to which they had been shaped by environmental interactions over time. However, it is possible that unintended and unknown off-target effects might arise on account of the CRISPR-Cas system. Such effects could be passed down in ignorance and eventually harm the carrier.

Because the CRISPR-Cas9 system is fairly new, and because much remains uncertain, the aforementioned examples of unintended harm are very real possibilities. However, these risks are present across many types of human subject research. Positive and negative pharmacologic pleiotropic effects have been identified in a wide variety of pharmaceuticals. Moreover, at certain dosages many mutagenic anticancer modalities, such as bleomycin, cyclophosphamide, mitomycin C, procarbazine, and radiation, have been found to induce germline mutations in animals and humans.<sup>114–117</sup> Yet without these drugs to combat the progression of the malignancy, many patients would die much more quickly, without any chance of achieving remission even for a period of time. Sometimes, risks involved may be worth the benefit. Fortunately, US federal regulations established for handling the permissibility of such research enable each prospective research proposal to be scrutinized by a given institution's institutional review board (IRB).<sup>118–120</sup> As more animal data are available, and as research proposals seek to engage in non-germline

experimentation, institutional IRBs will already have a constantly changing framework for deciding about whether the research CRISPR-Cas9 proposals are ethical. Even with the possibility of altering the germline unknowingly and indefinitely, the manner of weighing the possible risks and benefits of each study remains largely unchanged. In short, the uncertainty and risks presented by CRISPR-Cas9 are not wholly unlike those presented by other types of studies that include human subjects. It is an emphatically empirical question by how much, if at all, the risks presented by mutagenic agents differ from those presented by possible off-target effects of genomic engineering technology. This answer may be determined only by reliable data generated by rigorous, controlled experimentation. Thus, depending on the specifics of each research protocol, as determined by an IRB, nongermline experimentation in human subjects should be permitted.

A third concern is that, even if the CRISPR-Cas9 system works in humans as many hope—with great precision and with minimal off-target effects, there is increasing evidence that the causal weight of gene expression on certain phenotypic outcomes is questionable. Instead, in at least some diseases, environmental exposures and lifestyle play considerable roles. For example, Wu et al.<sup>121</sup> provided compelling evidence that intrinsic factors contribute 10% to 30% to the lifetime risk of developing cancer and that the rates of endogenous mutation accumulation by intrinsic processes do not adequately account for the observed cancer risks. As such, they maintain that cancer risk is significantly influenced by extrinsic factors. Additionally, many diseases, especially psychiatric diseases such as schizophrenia, bipolar disorder, autism spectrum disorder, and Alzheimer's disease, are largely thought to be of multigenic etiology.<sup>118,119</sup> It is unclear how genomic engineering might be effectively employed to coordinate genomic expression from multiple genes, even if it were determined for certain that some disease phenotypes result largely from inappropriate gene expression. Finally, genetic pleiotropic effects are an important source of phenotypic variability in humans. Even if it were determined that genes play *the most* important causal role in disease development, it is unclear how CRISPR-Cas systems might be able to account for pleiotropic effects, which may modify or obliterate some disease phenotypes entirely.

Although these concerns about limited therapeutic efficacy are warranted, they are insufficient to bar experimentation with CRISPR-Cas9. After all, if we were certain that this system would not yield any therapeutic potential, it would be unethical to use it for experiments with human subjects. But since we remain uncertain about the system's effects in humans, and since there is a theoretical possibility of significant benefit that is increasingly supported by recent scientific findings, experimentation on humans is ethically supported. Only with cautious, controlled experimentation can we learn whether using the CRISPR-Cas system is a reasonable approach to therapeutic development.

## II. CONCLUSION

Undoubtedly, CRISPR-Cas9 has great potential to revolutionize biological and biomedical innovation in ways not yet fully conceived. Nevertheless, eugenics lurks in the shadow of CRISPR. Any opening to germline, sperm, and egg modification is, simply

put, the opening of a return to the agenda of eugenics: the positive selection of “good” versions of the human genome and the weeding out of “bad” versions, not just for the health of an individual, but for the future of the species. To learn from errors of the past, to avert potentially lethal disasters, and to provide positive outcomes, it will be critical to know when to accelerate and when to apply the brakes, especially as this technology already comes equipped with such a prodigious accelerator.

## REFERENCES

1. Shakespeare W, Holland P. *Romeo and Juliet*. New York: Penguin Books; 2000. xlvii.
2. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. *Science*. 2014;346(6213):1258096.
3. Church G. Perspective: encourage the innovators. *Nature*. 2015;528(7580):S7.
4. Shah AN, Davey CF, Whitebirch AC, Miller AC, Moens CB. Rapid reverse genetic screening using CRISPR in zebrafish. *Nat Methods*. 2015;12(6):535–40.
5. Bhattacharya D, Marfo CA, Li D, Lane M, Khokha MK. CRISPR/Cas9: an inexpensive, efficient loss of function tool to screen human disease genes in *Xenopus*. *Dev Biol*. 2015;408(2):196–204.
6. Shalem O, Sanjana NE, Zhang F. High-throughput functional genomics using CRISPR-Cas9. *Nat Rev Genet*. 2015;16(5):299–311.
7. Bassett AR, Tibbit C, Ponting CP, Liu JL. Highly efficient targeted mutagenesis of *Drosophila* with the CRISPR/Cas9 system. *Cell Rep*. 2013;4(1):220–8.
8. Xiao D, Zhang W, Li Y, Liu K, Zhao J, Sun X, Shan L, Mao Q, Xia H. A novel luciferase knock-in reporter system for studying transcriptional regulation of the human Sox2 gene. *J Biotechnol*. 2016;219:110–6.
9. Bassett AR, Kong L, Liu JL. A genome-wide CRISPR library for high-throughput genetic screening in *Drosophila* cells. *J Genet Genomics*. 2015;42(6):301–9.
10. Flowers GP, Timberlake AT, McLean KC, Monaghan JR, Crews CM. Highly efficient targeted mutagenesis in axolotl using Cas9 RNA-guided nuclease. *Development*. 2014;141(10):2165–71.
11. Hodgkins A, Farne A, Perera S, Grego T, Parry-Smith DJ, Skarnes WC, Iyer V. WGE: a CRISPR database for genome engineering. *Bioinformatics*. 2015;31(18):3078–80.
12. Tu Z, Yang W, Yan S, Guo X, Li XJ. CRISPR/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases. *Mol Neurodegener*. 2015;10:35.
13. Beverley SM. Parasitology: CRISPR for *Cryptosporidium*. *Nature*. 2015;523(7561):413–4.
14. Dow LE. Modeling disease *in vivo* with CRISPR/Cas9. *Trends Mol Med*. 2015;21(10):609–21.
15. Carroll KJ, Makarewich CA, McAnally J, Anderson DM, Zentilin L, Liu N, Giacca M, Bassel-Duby R, Olson EN. A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9. *Proc Natl Acad Sci U S A*. 2016;113(2):338–43.
16. Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, Lv J, Xie X, Chen Y, Li Y, Sun Y, Bai Y, Songyang Z, Ma W, Zhou C, Huang J. CRISPR/Cas9-mediated gene editing in human triploid zygotes. *Protein Cell*. 2015;6(5):363–72.
17. Guo X, Li XJ. Targeted genome editing in primate embryos. *Cell Res*. 2015;25(7):767–8.
18. Kou Z, Wu Q, Kou X, Yin C, Wang H, Zuo Z, Zhuo Y, Chen A, Gao S, Wang X. CRISPR/Cas9-mediated genome engineering of the ferret. *Cell Res*. 2015;25(12):1372–5.
19. Zhu L, Mon H, Xu J, Lee JM, Kusakabe T. CRISPR/Cas9-mediated knockout of factors in non-homologous end joining pathway enhances gene targeting in silkworm cells. *Sci Rep*. 2015;5:18103.
20. Nodvig CS, Nielsen JB, Kogle ME, Mortensen UH. A CRISPR-Cas9 system for genetic engineering of filamentous fungi. *PLoS One*. 2015;10(7):e0133085.
21. Gratz SJ, Rubinstein CD, Harrison MM, Wildonger J, O’Connor-Giles KM. CRISPR-Cas9 genome editing in *Drosophila*. *Curr Protoc Mol Biol*. 2015;111:31.2.1–20.

22. Wang F, Shi Z, Cui Y, Guo X, Shi YB, Chen Y. Targeted gene disruption in *Xenopus laevis* using CRISPR/Cas9. *Cell Biosci.* 2015;5:15.
23. Hilton IB, D'Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, Gersbach CA. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. *Nat Biotechnol.* 2015;33(5):510–7.
24. Thakore PI, D'Ippolito AM, Song L, Safi A, Shivakumar NK, Kabadi AM, Kabadi AM, Reddy TE, Crawford GE, Gersbach CA. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. *Nat Methods.* 2015;12(12):1143–9.
25. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. *Nat Biotechnol.* 2014;32(4):347–55.
26. Schaeffer SM, Nakata PA. CRISPR/Cas9-mediated genome editing and gene replacement in plants: Transitioning from lab to field. *Plant Sci.* 2015;240:130–42.
27. Selle K, Barrangou R. CRISPR-based technologies and the future of food science. *J Food Sci.* 2015;80(11):R2367–72.
28. Shan Q, Wang Y, Li J, Gao C. Genome editing in rice and wheat using the CRISPR/Cas system. *Nat Protoc.* 2014;9(10):2395–410.
29. Li Y, Lin Z, Huang C, Zhang Y, Wang Z, Tang YJ, Chen T, Zhao X. Metabolic engineering of *Escherichia coli* using CRISPR-Cas9 mediated genome editing. *Metab Eng.* 2015;31:13–21.
30. Xiao D, Zhang W, Li Y, Liu K, Zhao J, Sun X, Shan L, Mao Q, Xia H. A novel luciferase knock-in reporter system for studying transcriptional regulation of the human Sox2 gene. *J Biotechnol.* 2016;219:110–6.
31. Bogerd HP, Kornepati AV, Marshall JB, Kennedy EM, Cullen BR. Specific induction of endogenous viral restriction factors using CRISPR/Cas-derived transcriptional activators. *Proc Natl Acad Sci U S A.* 2015;112(52):E7249–56.
32. Jo A, Ham S, Lee GH, Lee YI, Kim S, Lee YS, Shin JH, Lee Y. Efficient mitochondrial genome editing by CRISPR/Cas9. *Biomed Res Int.* 2015;2015:305716.
33. Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, Zetsche B, Shalem O, Wu X, Makarova KS, Koonin EV, Sharp PA, Zhang F. *In vivo* genome editing using *Staphylococcus aureus* Cas9. *Nature.* 2015;520(7546):186–91.
34. Tabebordbar M, Zhu K, Cheng JK, Chew WL, Widrick JJ, Yan WX, Maesner C, Wu EY, Xiao R, Ran FA, Cong L, Zhang F, Vandenberghe LH, Church GM, Wagers AJ. *In vivo* gene editing in dystrophic mouse muscle and muscle stem cells. *Science.* 2016;351(6271):407–11.
35. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell.* 2013;152(5):1173–83.
36. Torres-Ruiz R, Rodriguez-Perales S. CRISPR-Cas9: a revolutionary tool for cancer modelling. *Int J Mol Sci.* 2015;16(9):22151–68.
37. Yao S, He Z, Chen C. CRISPR/Cas9-mediated genome editing of epigenetic factors for cancer therapy. *Hum Gene Ther.* 2015;26(7):463–71.
38. Sanchez-Rivera FJ, Jacks T. Applications of the CRISPR-Cas9 system in cancer biology. *Nat Rev Cancer.* 2015;15(7):387–95.
39. Hart T, Chandrashekar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, Mero P, Dirks P, Sidhu S, Roth FP, Rissland OS, Durocher D, Angers S, Moffat J. High-Resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. *Cell.* 2015;163(6):1515–26.
40. Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Castellanos Rivera RM, Madhavan S, Pan X, Ran FA, Yan WX, Asokan A, Zhang F, Duan D, Gersbach CA. *In vivo* genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. *Science.* 2016;351(6271):403–7.



41. Long C, Amoasii L, Mireault AA, McAnally JR, Li H, Sanchez-Ortiz E, Bhattacharyya S, Shelton JM, Bassel-Duby R, Olson EN. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. *Science*. 2016;351(6271):400–3.
42. Hammond A, Galizi R, Kyrou K, Simoni A, Siniscalchi C, Katsanos D, Gribble M, Baker D, Marois E, Russell S, Burt A, Windbichler N, Crisanti A, Nolan T. A CRISPR-Cas9 gene drive system targeting female reproduction in the malaria mosquito vector *Anopheles gambiae*. *Nat Biotechnol*. 2016;34(1):78–83.
43. Sollelis L, Ghorbal M, MacPherson CR, Martins RM, Kuk N, Crobu L, Bastien P, Scherf A, Lopez-Rubio JJ, Sterkers Y. First efficient CRISPR-Cas9-mediated genome editing in *Leishmania* parasites. *Cell Microbiol*. 2015;17(10):1405–12.
44. Marraffini LA, Sontheimer EJ. CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. *Science*. 2008;322(5909):1843–5.
45. Wojtal D, Kemaladewi DU, Malam Z, Abdullah S, Wong TW, Hyatt E, Baghestani Z, Pereira S, Stavropoulos J, Mouly V, Mamchaoui K, Muntoni F, Voit T, Gonorazky HD, Dowling JJ, Wilson MD, Mendoza-Londono R, Ivakine EA, Cohn RD. Spell checking nature: versatility of CRISPR/Cas9 for developing treatments for inherited disorders. *Am J Hum Genet*. 2016;98(1):90–101.
46. Saayman S, Ali SA, Morris KV, Weinberg MS. The therapeutic application of CRISPR/Cas9 technologies for HIV. *Expert Opin Biol Ther*. 2015;15(6):819–30.
47. Pollack R. Eugenics lurk in the shadow of CRISPR. *Science*. 2015;348(6237):871.
48. Federal Registrar: The Daily Journal of the United States/ [homepage on the Internet]. [cited 2016 Jan 10]. Available from: <https://www.federalregister.gov/articles/2015/09/08/2015-21756/federal-policy-for-the-protection-of-human-subjects>.
49. Bhaya D, Davison M, Barrangou R. CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. *Annu Rev Genet*. 2011;45:273–97.
50. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P. CRISPR provides acquired resistance against viruses in prokaryotes. *Science*. 2007;315(5819):1709–12.
51. Koonin EV, Makarova KS. CRISPR-Cas: an adaptive immunity system in prokaryotes. *F1000 Biol Rep*. 2009;1:95.
52. Karginov FV, Hannon GJ. The CRISPR system: small RNA-guided defense in bacteria and archaea. *Mol Cell*. 2010;37(1):7–19.
53. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*. 2012;337(6096):816–21.
54. Jansen R, Embden JD, Gaastra W, Schouls LM. Identification of genes that are associated with DNA repeats in prokaryotes. *Mol Microbiol*. 2002;43(6):1565–75.
55. Koonin EV, Makarova KS. CRISPR-Cas: an adaptive immunity system in prokaryotes. *F1000 Biol Rep*. 2009;1:95.
56. Carroll D. A CRISPR approach to gene targeting. *Mol Ther*. 2012;20(9):1658–60.
57. Marraffini LA, Sontheimer EJ. CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea. *Nat Rev Genet*. 2010;11(3):181–90.
58. Chylinski K, Makarova KS, Charpentier E, Koonin EV. Classification and evolution of type II CRISPR-Cas systems. *Nucleic Acids Res*. 2014;42(10):6091–105.
59. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. RNA-programmed genome editing in human cells. *Elife*. 2013;2:e00471.
60. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. *Nat Protoc*. 2013;8(11):2281–308.
61. Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. *Science*. 2014;343(6166):80–4.
62. Yang H, Wang H, Jaenisch R. Generating genetically modified mice using CRISPR/Cas-mediated genome engineering. *Nat Protoc*. 2014;9(8):1956–68.

63. Bellec J, Bacchetta M, Losa D, Anegon I, Chanson M, Nguyen TH. CFTR inactivation by lentiviral vector-mediated RNA interference and CRISPR-Cas9 genome editing in human airway epithelial cells. *Curr Gene Ther*. 2015;15(5):447–59.
64. Chen Y, Cao J, Xiong M, Petersen AJ, Dong Y, Tao Y, Huang CT, Du Z, Zhang SC. Engineering human stem cell lines with inducible gene knockout using CRISPR/Cas9. *Cell Stem Cell*. 2015;17(2):233–44.
65. Fujii M, Matano M, Nanki K, Sato T. Efficient genetic engineering of human intestinal organoids using electroporation. *Nat Protoc*. 2015;10(10):1474–85.
66. Jing W, Zhang X, Sun W, Hou X, Yao Z, Zhu Y. CRISPR/CAS9-mediated genome editing of miRNA-155 inhibits proinflammatory cytokine production by RAW264.7 cells. *Biomed Res Int*. 2015;2015:326042.
67. Hou P, Chen S, Wang S, Yu X, Chen Y, Jiang M, Zhuang K, Ho W, Hou W, Huang J, Guo D. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. *Sci Rep*. 2015;5:15577.
68. Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R, Olson EN. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. *Science*. 2014;345(6201):1184–8.
69. Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. *Nat Biotechnol*. 2015;33(6):661–7.
70. Vinayak S, Pawlowic MC, Sateriale A, Brooks CF, Studstill CJ, Bar-Peled Y, Cipriano MJ, Striepen B. Genetic modification of the diarrhoeal pathogen *Cryptosporidium parvum*. *Nature*. 2015;523(7561):477–80.
71. Yang L, Guell M, Niu D, George H, Leshia E, Grishin D, Aach J, Shrock E, Xu W, Poci J, Cortazio R, Wilkinson RA, Fishman JA, Church G. Genome-wide inactivation of porcine endogenous retroviruses (PERVs). *Science*. 2015;350(6264):1101–4.
72. Čermák T, Baltes NJ, Cegan R, Zhang Y, Voytas DF. High-frequency, precise modification of the tomato genome. *Genome Biol*. 2015;16:232.
73. Du H, Zeng X, Zhao M, Cui X, Wang Q, Yang H, Cheng H, Yu D. Efficient targeted mutagenesis in soybean by TALENs and CRISPR/Cas9. *J Biotechnol*. 2016;217:90–7.
74. Jiang W, Brueggeman AJ, Horken KM, Plucinak TM, Weeks DP. Successful transient expression of Cas9 and single guide RNA genes in *Chlamydomonas reinhardtii*. *Eukaryot Cell*. 2014;13(11):1465–9.
75. Ito Y, Nishizawa-Yokoi A, Endo M, Mikami M, Toki S. CRISPR/Cas9-mediated mutagenesis of the RIN locus that regulates tomato fruit ripening. *Biochem Biophys Res Commun*. 2015;467(1):76–82.
76. Li JF, Zhang D, Sheen J. Cas9-based genome editing in *Arabidopsis* and tobacco. *Methods Enzymol*. 2014;546:459–72.
77. Li Z, Liu ZB, Xing A, Moon BP, Koellhoffer JP, Huang L, Ward RT, Clifton E, Falco SC, Cigan AM. Cas9-guide RNA directed genome editing in soybean. *Plant Physiol*. 2015;169(2):960–70.
78. Mikami M, Toki S, Endo M. Comparison of CRISPR/Cas9 expression constructs for efficient targeted mutagenesis in rice. *Plant Mol Biol*. 2015;88(6):561–72.
79. Svitashv S, Young JK, Schwartz C, Gao H, Falco SC, Cigan AM. Targeted mutagenesis, precise gene editing, and site-specific gene insertion in maize using Cas9 and guide RNA. *Plant Physiol*. 2015;169(2):931–45.
80. Woo JW, Kim J, Kwon SI, Corvalan C, Cho SW, Kim H, Kim SG, Kim ST, Choe S, Kim JS. DNA-free genome editing in plants with preassembled CRISPR-Cas9 ribonucleoproteins. *Nat Biotechnol*. 2015;33(11):1162–4.
81. Nihongaki Y, Kawano F, Nakajima T, Sato M. Photoactivatable CRISPR-Cas9 for optogenetic genome editing. *Nat Biotechnol*. 2015;33(7):755–60.
82. Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. *Science*. 2014;343(6166):80–4.
83. Yang H, Wang H, Jaenisch R. Generating genetically modified mice using CRISPR/Cas-mediated genome engineering. *Nat Protoc*. 2014;9(8):1956–68.



84. Bellec J, Bacchetta M, Losa D, Anegon I, Chanson M, Nguyen TH. CFTR inactivation by lentiviral vector-mediated RNA interference and CRISPR-Cas9 genome editing in human airway epithelial cells. *Curr Gene Ther*. 2015;15(5):447–59.
85. Wilde JJ, Petersen JR, Niswander L. Genetic, epigenetic, and environmental contributions to neural tube closure. *Annu Rev Genet*. 2014;48:583–611.
86. Greene ND, Stanier P, Copp AJ. Genetics of human neural tube defects. *Hum Mol Genet*. 2009;18(R2):R113–29.
87. Duester G. Retinoic acid synthesis and signaling during early organogenesis. *Cell*. 2008;134(6):921–31.
88. Stevenson RE, Hall JG. Human malformations and related anomalies. 3rd ed. New York: Oxford University Press; 2016.
89. Annas GJ, Grodin MA. The Nazi doctors and the Nuremberg Code: human rights in human experimentation. New York: Oxford University Press; 1992. xxii, 371 p. p.
90. Proctor R. Racial hygiene: medicine under the Nazis. Cambridge, Mass.: Harvard University Press; 1988.
91. Kevles DJ. Eugenics and human rights. *BMJ*. 1999;319(7207):435–8.
92. Adams, MB. The Wellborn science: eugenics in Germany, France, Brazil, and Russia. New York: Oxford University Press; 1990.
93. MacKenzie D. Eugenics in Britain. *Soc Stud Sci*. 1976;6(3-4):499–532.
94. Kevles DJ. In the name of eugenics: genetics and the uses of human heredity. 1st Harvard University Press pbk. ed. Cambridge, Mass.: Harvard University Press; 1995. xiii, 426 p. p.
95. Lombardo PA. A century of eugenics in America: from the Indiana experiment to the human genome era. Bloomington, Ind.: Indiana University Press; 2011. xi, 251 p. p.
96. Reilly PR. Eugenics and involuntary sterilization: 1907-2015. *Annu Rev Genomics Hum Genet*. 2015;16:351–68.
97. *Buck v. Bell*. May 2, 1927; Vol 274, US 201–7.
98. *Buck v. Bell*. Oyez. Chicago-Kent College of Law at Illinois Tech, n.d. Jan 10, 2016. [cited 2016 Jan 10]. Available from: <https://www.oyez.org/cases/1900-1940/274us200>.
99. Lombardo PA. Three generations, no imbeciles: eugenics, the Supreme Court, and *Buck v. Bell*. Baltimore: Johns Hopkins University Press; 2008. xiv, 365 p. p.
100. Seligman HK, Schillinger D. Hunger and socioeconomic disparities in chronic disease. *N Engl J Med*. 2010;363(1):6–9.
101. Cutting remarks: A gene editing company files for an IPO. *Economist*. 2016 Jan: 54-55.
102. Bolukbasi MF, Gupta A, Wolfe SA. Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery. *Nat Methods*. 2016;13(1):41–50.
103. Chu VT, Weber T, Wefers B, Wurst W, Sander S, Rajewsky K, Kühn R. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. *Nat Biotechnol*. 2015;33(5):543–8.
104. Horii T, Hatada I. Challenges to increasing targeting efficiency in genome engineering. *J Reprod Dev*. 2016;62(1):7–9.
105. Iyer V, Shen B, Zhang W, Hodgkins A, Keane T, Huang X, Skarnes WC. Off-target mutations are rare in Cas9-modified mice. *Nat Methods*. 2015;12(6):479.
106. Keener AB. Delivering the goods: scientists seek a way to make CRISPR-Cas gene editing more targeted. *Nat Med*. 2015;21(11):1239–41.
107. Peng R, Lin G, Li J. Potential Pitfalls of CRISPR/Cas9-mediated genome editing. *FEBS J*. 2016;283(7):1218–31.
108. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. *Science*. 2016;351(6268):84–8.
109. Zhang XH, Tee LY, Wang XG, Huang QS, Yang SH. Off-target Effects in CRISPR/Cas9-mediated Genome Engineering. *Mol Ther Nucleic Acids*. 2015;4:e264.

110. Veres A, Gosis BS, Ding Q, Collins R, Ragavendran A, Brand H, Erdin S, Cowan CA, Talkowski ME, Musunuru, K. Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. *Cell Stem Cell* 2014;15(1):27–30.
111. Knight SC, Xie L, Deng W, Guglielmi B, Witkowsky LB, Bosanac L, Zhang ET, E Beheiry M, Masson JB, Dahan M, Liu Z, Doudna JA, Tjian R. Dynamics of CRISPR-Cas9 genome interrogation in living cells. *Science*. 2015;350(6262):823–6.
112. Code of Federal Regulations: Good Laboratory Practice for Nonclinical Laboratory Studies, 21 C.F.R. Sect. 58 (2015).
113. Rowe SM, Verkman AS. Cystic fibrosis transmembrane regulator correctors and potentiators. *Cold Spring Harb Perspect Med*. 2013;3(7).
114. Glen CD, Smith AG, Dubrova YE. Single-molecule PCR analysis of germ line mutation induction by anticancer drugs in mice. *Cancer Res*. 2008;68(10):3630–6.
115. Brinkworth MH. Paternal transmission of genetic damage: findings in animals and humans. *Int J Androl*. 2000;23(3):123–35.
116. Pletsa V, Valavanis C, van Delft JH, Steenwinkel MJ, Kyrtopoulos SA. DNA damage and mutagenesis induced by procarbazine in lambda lacZ transgenic mice: evidence that bone marrow mutations do not arise primarily through miscoding by O6-methylguanine. *Carcinogenesis*. 1997;18(11):2191–6.
117. Dubrova YE. Monitoring of radiation-induced germline mutation in humans. *Swiss Med Wkly*. 2003;133(35-36):474–8.
118. Code of Federal Regulations: IRB Review of Research, 45 C.F.R. Sect. 46.109 (2015).
119. Code of Federal Regulations: Protection of Human Subjects, 21 C.F.R. Sect. 50 (2015).
120. Code of Federal Regulations: Institutional Review Boards, 21 C.F.R. Sect. 56 (2015).
121. Yehuda S, Mostofsky DI. *Nutrients, stress, and medical disorders*. Totowa, NJ: Humana Press; 2006.
122. Sullivan PF, Daly MJ, O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. *Nat Rev Genet*. 2012;13(8):537–51.

